CNX acquires four cancer drugs from Clinigen
The purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene
Read Moreby John Pinching | Aug 14, 2023 | News | 0
The purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene
Read Moreby Selina McKee | Jul 13, 2020 | News | 0
Clinigen has bagged a US orphan drug designation (ODD) for its investigational Amyotrophic Lateral Sclerosis (ALS) treatment aldesleukin.
Read Moreby Anna Smith | Oct 17, 2019 | News | 0
The Progenics drug is currently not approved for any indication outside of the US.
Read Moreby Selina McKee | Jul 26, 2018 | News | 0
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Read Moreby Selina McKee | May 23, 2018 | News | 0
Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
